| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Science Applications International Corporation-Frederick, Inc., and 2 Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland
Requests for reprints: Giovanni Melillo, Developmental Therapeutics Program, Tumor Hypoxia Laboratory, National Cancer Institute at Frederick, Building 432, Room 218, Frederick, MD 21702. Phone: 301-846-5050; Fax: 301-846-6081; E-mail: melillog{at}ncifcrf.gov.
The identification of small molecules that inhibit the sequence-specific binding of transcription factors to DNA is an attractive approach for regulation of gene expression. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that controls genes involved in glycolysis, angiogenesis, migration, and invasion, all of which are important for tumor progression and metastasis. To identify inhibitors of HIF-1 DNA-binding activity, we expressed truncated HIF-1
and HIF-1ß proteins containing the basic-helix-loop-helix and PAS domains. Expressed recombinant HIF-1 and HIF-1ß proteins induced a specific DNA-binding activity to a double-stranded oligonucleotide containing a canonical hypoxia-responsive element (HRE). One hundred twenty-eight compounds previously identified in a HIF-1–targeted cell-based high-throughput screen of the National Cancer Institute 140,000 small-molecule library were tested in a 96-well plate ELISA for inhibition of HIF-1 DNA-binding activity. One of the most potent compounds identified, echinomycin (NSC-13502), a small-molecule known to bind DNA in a sequence-specific fashion, was further investigated. Electrophoretic mobility shift assay experiments showed that NSC-13502 inhibited binding of HIF-1 and HIF-1ß proteins to a HRE sequence but not binding of the corresponding proteins to activator protein-1 (AP-1) or nuclear factor-
B (NF-B) consensus sequences. Interestingly, chromatin immunoprecipitation experiments showed that NSC-13502 specifically inhibited binding of HIF-1 to the HRE sequence contained in the vascular endothelial growth factor (VEGF) promoter but not binding of AP-1 or NF-B to promoter regions of corresponding target genes. Accordingly, NSC-13502 inhibited hypoxic induction of luciferase in U251-HRE cells and VEGF mRNA expression in U251 cells. Our results indicate that it is possible to identify small molecules that inhibit HIF-1 DNA binding to endogenous promoters.
This article has been cited by other articles:
|
|
 |
|
  C. Bianco, C. Cotten, E. Lonardo, L. Strizzi, C. Baraty, M. Mancino, M. Gonzales, K. Watanabe, T. Nagaoka, C. Berry, et al. Cripto-1 Is Required for Hypoxia to Induce Cardiac Differentiation of Mouse Embryonic Stem Cells Am. J. Pathol., November 1, 2009; 175(5): 2146 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hu, K. Kirito, K. Yoshida, T. Mitsumori, K. Nakajima, Y. Nozaki, S. Hamanaka, T. Nagashima, M. Kunitama, K. Sakoe, et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan Mol. Cancer Ther., August 1, 2009; 8(8): 2329 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kim, I. C. Bagchi, and M. K. Bagchi Signaling by Hypoxia-Inducible Factors Is Critical for Ovulation In Mice Endocrinology, July 1, 2009; 150(7): 3392 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Gerard, S. Poncin, J.-N. Audinot, J.-F. Denef, and I. M. Colin Iodide deficiency-induced angiogenic stimulus in the thyroid occurs via HIF- and ROS-dependent VEGF-A secretion from thyrocytes Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1414 - E1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thangasamy, J. Rogge, and S. Ammanamanchi Recepteur d'Origine Nantais Tyrosine Kinase Is a Direct Target of Hypoxia-inducible Factor-1{alpha}-mediated Invasion of Breast Carcinoma Cells J. Biol. Chem., May 22, 2009; 284(21): 14001 - 14010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Amann, U. Maegdefrau, A. Hartmann, A. Agaimy, J. Marienhagen, T. S. Weiss, O. Stoeltzing, C. Warnecke, J. Scholmerich, P. J. Oefner, et al. GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis Am. J. Pathol., April 1, 2009; 174(4): 1544 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, C. K. Veena, J. B. Morgan, K. A. Mohammed, M. B. Jekabsons, D. G. Nagle, and Y.-D. Zhou Methylalpinumisoflavone Inhibits Hypoxia-inducible Factor-1 (HIF-1) Activation by Simultaneously Targeting Multiple Pathways J. Biol. Chem., February 27, 2009; 284(9): 5859 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Regazzetti, P. Peraldi, T. Gremeaux, R. Najem-Lendom, I. Ben-Sahra, M. Cormont, F. Bost, Y. Le Marchand-Brustel, J.-F. Tanti, and S. Giorgetti-Peraldi Hypoxia Decreases Insulin Signaling Pathways in Adipocytes Diabetes, January 1, 2009; 58(1): 95 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-M. Zou and A. Maitra Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration Mol. Cancer Ther., July 1, 2008; 7(7): 2012 - 2021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Peixoto, Y. Liu, S. Depauw, M.-P. Hildebrand, D. W. Boykin, C. Bailly, W. D. Wilson, and M.-H. David-Cordonnier Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication Nucleic Acids Res., June 1, 2008; 36(10): 3341 - 3353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li, L. Chen, F. Yi, M. Xia, and P.-L. Li Salt-Sensitive Hypertension Induced by Decoy of Transcription Factor Hypoxia-Inducible Factor-1{alpha} in the Renal Medulla Circ. Res., May 9, 2008; 102(9): 1101 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lin, C. A. David, J. B. Donnelly, M. Michaelides, N. S. Chandel, X. Huang, U. Warrior, F. Weinberg, K. V. Tormos, S. W. Fesik, et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation PNAS, January 8, 2008; 105(1): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Park, W.-S. Shin, and S.-K. Kim In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., January 1, 2008; 61(1): 163 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rapisarda and G. Melillo HIF-1 Inhibitors: Novel Opportunities for Cancer Therapy ASCO Educational Book, January 1, 2008; 2008(1): 543 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Turcotte and A. J. Giaccia Targeted Therapy for the Loss of the Tumor Suppressor Gene von Hippel-Lindau through Synthetic Lethality ASCO Educational Book, January 1, 2008; 2008(1): e15 - e18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Sutphin, D. A. Chan, J. M. Li, S. Turcotte, A. J. Krieg, and A. J. Giaccia Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells Cancer Res., June 15, 2007; 67(12): 5896 - 5905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Cairns, I. Papandreou, P. D. Sutphin, and N. C. Denko Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy PNAS, May 29, 2007; 104(22): 9445 - 9450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Creighton-Gutteridge, J. H. Cardellina II, A. G. Stephen, A. Rapisarda, B. Uranchimeg, K. Hite, W. A. Denny, R. H. Shoemaker, and G. Melillo Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1{alpha} Protein Accumulation by NSC 644221 Clin. Cancer Res., February 1, 2007; 13(3): 1010 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Nickols, C. S. Jacobs, M. E. Farkas, and P. B. Dervan Improved nuclear localization of DNA-binding polyamides Nucleic Acids Res., January 28, 2007; 35(2): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li, F. Yi, C. M. Sundy, L. Chen, M. L. Hilliker, D. K. Donley, D. B. Muldoon, and P.-L. Li Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys Am J Physiol Renal Physiol, January 1, 2007; 292(1): F207 - F216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Melillo Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy Mol. Cancer Res., September 1, 2006; 4(9): 601 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pacary, H. Legros, S. Valable, P. Duchatelle, M. Lecocq, E. Petit, O. Nicole, and M. Bernaudin Synergistic effects of CoCl2 and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells J. Cell Sci., July 1, 2006; 119(13): 2667 - 2678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Melillo and G. L. Semenza Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics. Cancer Res., May 1, 2006; 66(9): 4558 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Cairns, I. Papandreou, and N. Denko Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
